XRTX — XORTX Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$4.81m
- CA$3.67m
Annual balance sheet for XORTX Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 14.9 | 10.4 | 3.45 | 2.47 | 0.865 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.041 | 0.082 | 0.061 | 0.018 | 0.08 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 16 | 10.9 | 4.07 | 2.68 | 1.26 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.093 | 0.024 | 0.035 | 0.037 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Total Assets | 17.4 | 12.4 | 5.47 | 4.09 | 2.68 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.555 | 1.52 | 0.295 | 0.758 | 0.599 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.19 | 5.38 | 0.826 | 0.758 | 0.599 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 13.2 | 7 | 4.64 | 3.34 | 2.08 |
| Total Liabilities & Shareholders' Equity | 17.4 | 12.4 | 5.47 | 4.09 | 2.68 |
| Total Common Shares Outstanding |